Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leisha A Emens

Showing results (81-90 of 114) with videos related to

Pageof 12
Sort By:
Cancer|January 31, 2018
Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancerAnya Litvak, Bhavina Batukbhai, Stuart D Russell, et al.
Gynecologic Oncology|June 18, 2019
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancersJoyce F Liu, Michael Gordon, Jennifer Veneris, et al.
Clinical Breast Cancer|February 6, 2010
Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancerSaranya Chumsri, Stacie Jeter, Lisa K Jacobs, et al.
Gynecologic Oncology|February 14, 2025
A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancerStéphanie Gaillard, Neha Verma, Maureen Berg, et al.
The Lancet. Oncology|December 2, 2019
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trialPeter Schmid, Hope S Rugo, Sylvia Adams, et al.
Journal of the National Cancer Institute|February 1, 2021
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 StudyLeisha A Emens, Luciana Molinero, Sherene Loi, et al.
Breast Cancer Research and Treatment|February 26, 2011
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancerRoisin M Connolly, Michelle A Rudek, Elizabeth Garrett-Mayer, et al.
The Lancet. Oncology|October 1, 2020
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trialLeisha A Emens, Francisco J Esteva, Mark Beresford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancerRichard C Zellars, Vered Stearns, Deborah Frassica, et al.
NPJ Breast Cancer|April 21, 2022
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancersPooja Srivastava, Tiannan Wang, Beth Z Clark, et al.
Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
Cancer|January 31, 2018
Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancerAnya Litvak, Bhavina Batukbhai, Stuart D Russell, et al.
Gynecologic Oncology|June 18, 2019
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancersJoyce F Liu, Michael Gordon, Jennifer Veneris, et al.
Clinical Breast Cancer|February 6, 2010
Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancerSaranya Chumsri, Stacie Jeter, Lisa K Jacobs, et al.
Gynecologic Oncology|February 14, 2025
A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancerStéphanie Gaillard, Neha Verma, Maureen Berg, et al.
The Lancet. Oncology|December 2, 2019
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trialPeter Schmid, Hope S Rugo, Sylvia Adams, et al.
Journal of the National Cancer Institute|February 1, 2021
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 StudyLeisha A Emens, Luciana Molinero, Sherene Loi, et al.
Breast Cancer Research and Treatment|February 26, 2011
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancerRoisin M Connolly, Michelle A Rudek, Elizabeth Garrett-Mayer, et al.
The Lancet. Oncology|October 1, 2020
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trialLeisha A Emens, Francisco J Esteva, Mark Beresford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancerRichard C Zellars, Vered Stearns, Deborah Frassica, et al.
NPJ Breast Cancer|April 21, 2022
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancersPooja Srivastava, Tiannan Wang, Beth Z Clark, et al.
Pageof 12